Results 171 to 180 of about 1,288 (185)

Oral Ibrexafungerp Outcomes in Subjects With Refractory Vulvovaginal Candidiasis From an Open-Label Study (FURI) [A122]

Obstetrics & Gynecology, 2022
INTRODUCTION: Ibrexafungerp, a novel one-day oral triterpenoid antifungal, was recently approved for the treatment of vulvovaginal candidiasis (VVC). Ibrexafungerp is a fungicidal with broad activity against Candida species, including fluconazole-resistant strains.
Oluwatosin Goje, Thomas King, David Angulo, Nkechi Azie   +3 more
openaire   +1 more source

A cost-effectiveness analysis of the use of oral ibrexafungerp versus fluconazole for acute vulvovaginal candidiasis in the UK NHS primary care service.

The British journal of general practice : the journal of the Royal College of General Practitioners
BACKGROUND Vulvovaginal Candidiasis (VVC) is a fungal infection causing inflammation of the vagina and/or the vulva. Symptoms include itching, irritation, and discharge.
V. Shah, Anjali Cyril, Peter Koleoso, Arunesh Ragutharan, M. Faiz, Pathusha Pushpakanthan   +5 more
semanticscholar   +1 more source

Ibrexafungerp, a Novel Oral Antifungal, Demonstrates No Reproductive or Developmental Harm in Preclinical Models [25J]

Obstetrics & Gynecology, 2019
INTRODUCTION: The treatment of fungal infections, like Vulvovaginal Candidiasis (VVC), during pregnancy is difficult due to the teratogenicity associated with existing anti-fungal treatment options. VVC, also known as yeast infection, is especially common during pregnancy. Fluconazole, the oral standard of care, is not approved
Christina Carruthers, Stephen Barat, David Angulo, Porsha Thomas, Elise Lewis, Ryan Sobel   +5 more
openaire   +1 more source

In Vitro Activity of Ibrexafungerp (SCY-078) Against Candida spp. (Including Fluconazole-Resistant Isolates) [14OP]

Obstetrics & Gynecology, 2019
INTRODUCTION: Vulvovaginal candidiasis (VVC) is a common fungal infection caused by Candida spp., with only one oral treatment, fluconazole, currently approved in the U.S. Another oral option is desirable, particularly with azole resistance on the rise among some Candida spp.
Katyna Borroto-Esoda, Stephen Barat, David Angulo, Ryan Sobel   +3 more
openaire   +1 more source

A Phase 2b, Dose-Finding Study Evaluating Oral Ibrexafungerp vs Fluconazole in Vulvovaginal Candidiasis (DOVE) [24J]

Obstetrics & Gynecology, 2019
INTRODUCTION: Ibrexafungerp (IBX, formerly SCY-078) is a novel IV/oral antifungal currently in development for the treatment of invasive and mucocutaneous fungal infections. IBX has broad activity against Candida spp., including azole-resistant strains.
Rebecca Cadet, Mihaela Tufa, David Angulo, Paul Nyirjesy   +3 more
openaire   +1 more source

Ibrexafungerp to treat acute vulvovaginal candidiasis

Nature Reviews Urology, 2021
openaire   +2 more sources

Yeasts from blood cultures in the wake of the COVID-19 pandemic in a tertiary care hospital: Shift in species epidemiology, steady low antifungal resistance and full in vitro ibrexafungerp activity.

Medical Mycology, 2023
Judith Díaz-García, Aina Mesquida, M. Machado, C. Sánchez-Carrillo, Patricia Muñoz, P. Escribano, J. Guinea   +6 more
semanticscholar   +1 more source

A phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of once monthly oral ibrexafungerp for prevention of recurrent vulvovaginal candidiasis (VVC)

American Journal of Obstetrics and Gynecology, 2023
Goje O, A. N, K. T, A. D.
semanticscholar   +1 more source

Ibrexafungerp bei akuter vulvovaginaler Candidose effektiv und sicher

Geburtshilfe und Frauenheilkunde, 2022
openaire   +1 more source

Ibrexafungerp (Brexafemme) for the Treatment of Vulvovaginal Candidiasis.

American family physician, 2022
Kelsea, Woolfolk, Jonathan, Hughes
openaire   +1 more source